Testosterone is the hormone nobody checks in women. Nico Misleh, MSN, FNP-C sat in an OB-GYN office with his wife not long ago and watched it play out. Nobody ordered it. It did not come up. He checks it on every female patient he has, his students all check it, and inside that bubble it starts to feel like standard practice. It isn't.

So the first half of this episode is women. Testosterone isn't a male hormone that women happen to carry a little of. They have it by design. It's doing work on lean body mass, on body composition, on cognition and mental clarity, on drive through a dopaminergic pathway, on libido. Bone too. It has effects on bone mineral density that don't run through estrogen, and progesterone does the same thing to bone, so this isn't a testosterone-only story. The woman on estradiol and progesterone can be a lot better and still not be all the way there. Her hot flashes eased and her sleep improved. Her libido is still flat, and she can't hold muscle no matter how hard she trains. That's frequently a testosterone story, and it stays unnamed. Testosterone did not come up once in his own NP program. Not for women, not for men.

Androgenic side effects come up. They're real at supraphysiologic doses and uncommon at replacement doses handled carefully. The reference range is the harder problem. It was built on a population that includes symptomatic women, so it can tell you what's typical and it can't tell you what's optimal. His line: we're the cardiologists who never got taught how to use an EKG.

Men get the second half. His position is that testosterone is still under-prescribed in men, and that where it does get prescribed, it's often done badly. Total testosterone is probably the least useful number on the panel. Free testosterone is what the cell can actually use. SHBG is the little protein he calls a Pac-Man, binding testosterone up and holding it hostage where tissue can't reach it, and in his opinion you can't interpret a testosterone level without it. He walks a case. Total of 5 or 600, SHBG north of 100, free testosterone nobody ordered. That man has low testosterone and it will never show up on paper, because the value that would have caught it was never drawn. Nico is plain about not having known what SHBG was either. In his words, we're all in this boat together.

Then the hands-on stretch. Intramuscular versus subcutaneous and what the head-to-head data actually showed, needle gauge and length, post-injection pain and how to settle it, compounded creams and gels, why he isn't a fan of pellets in either sex, and the dosing philosophy he teaches. You aim for the maximum effective dose, not the smallest one that moves a lab value, because you're restoring a molecule the body already makes.

Male testosterone therapy is module two of the HRT University® Master Course. Testosterone in women is the testosterone section of module three, the female module. SHBG runs through both.

The Master Course is jointly accredited through Pinnacle Conference, LLC (ACCME, ACPE, ANCC). Earn 30 CE hours, including 12 hours of pharmacology.

Master Course: https://hrtuniversity.com/hrtcourse/

More episodes: https://hrtuniversity.com/hrtu-podcast/

The Second Opinion Newsletter: https://nicomislehnp.kit.com/8050eeea5f

Provider community: https://www.facebook.com/groups/1179376819949373/

Progesterone gets filed under women's health, and inside that, under uterine health. Nico Misleh, MSN, FNP-C argues that both filings are too narrow and that a provider prescribing progesterone only for endometrial protection is working with roughly a quarter of the picture.

The mechanism he builds the episode on is allopregnanolone. Progesterone converts through 5-alpha reductase into a neurosteroid that acts as a positive allosteric modulator at GABA-A receptors. GABA is the brake of the brain. When progesterone falls, that braking capacity falls with it, which is why anxiety, irritability, and fractured sleep tend to arrive in the same patient. He also separates progesterone from progestins, since medroxyprogesterone acetate is testosterone-derived, cannot convert to allopregnanolone, and binds androgen, glucocorticoid, and mineralocorticoid receptors, which is where its side effect profile comes from.

Then he turns to men. Men make progesterone. Nico covers neuroprotection, sleep through that same pathway, cortisol buffering, and prostate tissue, along with the presentations where he reaches for it most: anxiety, traumatic brain injury, PTSD, and BPH. Male dosing is not female dosing, and he is candid that his own hesitation kept him from using it for years.

If you have men with optimized testosterone and thyroid who still sleep badly and still feel wired, this is the variable worth adding to the picture.

Progesterone is taught in depth across the advanced female and adjunct hormone modules of the HRT University Master Course.

The HRT University® Master Course is jointly accredited through Pinnacle Conference, LLC (ACCME, ACPE, ANCC). Earn 30 CE hours, including 12 hours of pharmacology.

Master Course: https://hrtuniversity.com/hrtcourse/

More episodes: https://hrtuniversity.com/hrtu-podcast/

Nico's clinical email: https://nicomislehnp.kit.com/8050eeea5f

Provider community: https://www.facebook.com/groups/1179376819949373/

DHT gets blamed for hair loss more than almost anything else, and Nico Misleh, MSN, FNP-C thinks that blame is misplaced. In this episode he makes the case that dihydrotestosterone is not the villain it has been made out to be. It is a necessary hormone that keeps doing real work long after puberty, and for a patient who is losing hair it is usually a downstream signal rather than the thing actually driving the problem.

DHT does bind androgen-sensitive follicles and it does play a part in miniaturization. That piece is real. The question that almost never gets asked is why 5-alpha reductase, the enzyme that turns testosterone into DHT, is running high in the first place. That is where the clinical opportunity lives. Nico ties elevated 5-alpha reductase back to what he teaches inside the Big Five of metabolic dysfunction: insulin resistance and hyperinsulinemia, chronic inflammation, histamine, cortisol, and low thyroid function. Hair loss turns out to be one more way that same broken terrain shows itself.

He also clears up something that often gets taught backward. Estrogen does not push 5-alpha reductase up on its own. In a healthy balance it holds it down. It is estrogen dominance, dragging progesterone lower and pushing blood sugar higher, that moves the needle. That is also why a serum DHT value can point you the wrong way, and why Nico leans on fasting insulin, free T3, cortisol, and a hard look at gut and metabolic health instead. Improve the terrain and DHT often settles on its own.

Then he gets practical. Why he will not put a patient, man or woman, on oral finasteride or dutasteride after seeing what post-finasteride syndrome can do. Where low-dose topical finasteride and minoxidil honestly land, and where they fall short. And the pro-metabolic route he actually uses, including the compounded hair serum he built around progesterone, caffeine, melatonin, and thyroid to outcompete DHT at the follicle and calm the inflammation while supporting the energy a follicle needs to grow. It is slow work, so give it three to six months before you judge it.

If you have a patient stuck getting the same block-DHT answer over and over, this episode hands you a better way to read the case. Hair loss is a symptom worth listening to, not just a part of getting older.

Hair loss sits inside Nico's Big Five framework, the backbone of Module 1 in the HRT University Master Course.

Read the full article: https://hrtuniversity.com/dht-causes-hair-loss/

More episodes: https://hrtuniversity.com/hrtu-podcast/

The HRT University Master Course is jointly accredited through Pinnacle Conference, LLC (ACCME, ACPE, ANCC). Earn 30 CE hours, including 12 hours of pharmacology.

Master Course: https://hrtuniversity.com/hrtcourse/

Nico's weekly clinical email: https://nicomislehnp.kit.com/8050eeea5f

Provider community: https://www.facebook.com/groups/1179376819949373/

Cortisol is one of the most misunderstood hormones in practice, and one of the most over-tested. In this episode, Nico Misleh, MSN, FNP-C makes the case that cortisol is a signal, not the root problem. You rarely need to measure it directly. What you do need to understand is what chronic cortisol is quietly doing to every hormone you're trying to optimize.

Nico walks through the mechanism. Chronically elevated cortisol tanks free testosterone in men through competition at the hypothalamic level and blunted GnRH signaling. In women it suppresses ovulation and shortens the luteal phase, and that is the real reason progesterone stays low, not the old pregnenolone steal theory. It shunts T4 away from free T3 toward reverse T3, which is why a normal TSH tells you so little and free T3 tells you almost everything. Over time it dysregulates blood sugar, drives visceral fat, and feeds a slow inflammatory flywheel.

Then the practical side. Why serum and salivary cortisol testing so often fail to line up with how a patient actually feels. Why cortisol dysfunction is almost always downstream of a broken metabolic environment. And what Nico treats instead: the terrain itself, thyroid and free T3, the sex hormones, gut and metabolic health, sleep, stress load, and eating patterns, with HRT as the backbone of that restoration. This is not an adrenal fatigue protocol.

If you have a few patients who never quite respond to HRT the way the rest do, cortisol belongs on your differential, not as a lab to run, but as a lifestyle and metabolic picture to read.

Cortisol sits inside Nico's Big Five framework, the organizing model of Module 1 in the HRT University Master Course.

The HRT University® Master Course is jointly accredited through Pinnacle Conference, LLC (ACCME, ACPE, ANCC). Earn 30 CE hours, including 12 hours of pharmacology.

Master Course: https://bit.ly/4twBb0D

Nico's weekly clinical email: https://nicomislehnp.kit.com/8050eeea5f

Provider community: https://www.facebook.com/groups/1179376819949373/

You have a patient who is doing everything right on paper. Hormones optimized, sleep handled, xenoestrogen exposure coming down. And still the weight will not move, the thyroid numbers look off, and the inflammation lingers. In this episode Nico Misleh, MSN, FNP-C, makes the case that the missing variable is often sitting in the patient’s diet: seed oils, and the polyunsaturated fatty acids, or PUFAs, they deliver.

Seed oils are the base fat in nearly every processed and restaurant food, and per capita linoleic acid intake has roughly tripled since the early 1900s. Nico walks through why that matters at the level of the cell. Using the cast iron versus stainless steel analogy from Module 1, he explains how PUFAs oxidize, form oxidized linoleic acid metabolites known as OXLAMs, and damage the mitochondria that every steroid hormone depends on. When mitochondria leak energy, cells drop from oxidative phosphorylation into inefficient glycolysis, progesterone and pregnenolone synthesis falls, thyroid signaling suffers at the receptor, and aromatase climbs. This is PUFAs, number four of the Big Five, and it compounds with endotoxin, cortisol, estrogen, and serotonin.

He also separates what is mechanistically settled from what the clinical trial literature has not yet caught up to, explains why linoleic acid stored in fat has a half life close to two years, and shows how to raise diet with patients without tipping them into fear. This is the mechanism-first explanation for why some patients stall on a textbook HRT protocol, and what to do about it.

Hosted by Nico Misleh, MSN, FNP-C, founder of HRT University. The HRT University® Podcast is provider-facing hormone education grounded in physiology and mechanism. For the full framework, including the PUFA and Big Five sections in Module 1, explore the HRT University Master Course, jointly accredited through Pinnacle Conference LLC (ACCME, ACPE, ANCC).

Master Course: https://bit.ly/4twBb0D

Newsletter: https://nicomislenp.kit.com/8050eeea5f

Provider community: https://www.facebook.com/groups/1179376819949373/

A century ago the average girl reached her first period at 16 or 17. Today it is closer to 12, and breast development is turning up routinely at 6, 7, even 8 years old. Genetics do not move that fast. Something in the environment is switching the reproductive axis on years ahead of schedule, and in this episode Nico Misleh, MSN, FNP-C, makes the case that the driver is xenoestrogens, and that it lands directly in your exam room.

Xenoestrogens are estrogens from outside the body: the parabens, phthalates, pesticides, plastics, fragrances, and even some essential oils that bind estrogen receptors closely enough that the receptor cannot reliably tell them apart from the real thing. Exposure begins in utero and never fully stops, so it is both continuous and cumulative. Nico connects that early and prolonged estrogen signaling to the patients now arriving in HRT clinics in their 20s and 30s with pronounced estrogen dominance and progesterone deficiency, at times more severe than the perimenopausal patients down the hall.

He reframes age of menarche and environmental exposure history as clinical variables that belong on the intake form, explains why some patients fail to respond to progesterone because of receptor competition rather than a dosing problem, and walks through the exposure-reduction conversation that lets the hormones you prescribe actually win at the receptor. This is the lifespan view of the Big Five: the same xenoestrogen load that pulled puberty early keeps shaping estrogen dominance, PCOS, and endometriosis in adults.

Hosted by Nico Misleh, MSN, FNP-C, founder of HRT University. The HRT University Podcast is provider-facing hormone education grounded in physiology and mechanism. For the full clinical framework, including the xenoestrogen section in Module 1, explore the HRT University Master Course, jointly accredited through Pinnacle Conference LLC (ACCME, ACPE, ANCC): https://bit.ly/4twBb0D

Newsletter: https://nicomislenp.kit.com/8050eeea5f
Provider community: https://www.facebook.com/groups/1179376819949373/

You have seen this patient. Her estrogen reads optimal. You have checked it two or three times. And she is still bloated, still constipated, still dealing with breast tenderness, heavy bleeding, and the irritability that shows up like clockwork before her period. The labs say one thing. The woman in front of you says another.

In this episode, Nico Misleh, MSN, FNP-C breaks down the estrobolome: the collection of gut bacteria and bacterial genes that decide whether estrogen leaves the body or gets sent back into circulation. The liver does its job. It conjugates estrogen and packages it for excretion through bile and stool. Then beta-glucuronidase, produced by a disrupted microbiome, cleaves that package open and frees the estrogen to reabsorb through the gut wall and travel back to the liver. This is enterohepatic recirculation, and it is a problem of accumulation. It builds quietly for years, then surfaces as estrogen dominance, PCOS, PMDD, fibroids, and elevated breast cancer risk.

Nico connects the mechanism to what you can actually do. Why industrialized guts carry higher beta-glucuronidase capacity. Why a menopausal woman can run higher circulating estrogen than expected with no progesterone to counterbalance it. Why a patient who reacts to a low dose of estrogen may have a gut problem, not a dosing problem. Then he walks through the targeted interventions he reaches for first: the raw carrot, coffee and gut motility, glycine and taurine for phase two liver detoxification, and the role of progesterone and thyroid in clearing estrogen instead of recycling it.

HRT University is a physiology-first clinical education program for licensed providers. Jointly accredited through Pinnacle Conference LLC (ACCME, ACPE, ANCC) for 30 CEUs.

Learn more about the Master Course: https://bit.ly/4twBb0D HRTU Newsletter: https://nicomislenp.kit.com/8050eeea5f Join the HRT University Facebook Group: https://www.facebook.com/groups/1179376819949373/

Polycystic ovary syndrome is no longer called polycystic ovary syndrome. A landmark consensus study in The Lancet, built on 22,000 clinicians and patients across 11 years of global consultation, has renamed the condition polyendocrine metabolic ovarian syndrome, or PMOS. The cysts were never the story. The metabolism was. The hormones were. The gut was.

In our 100th episode, Nico Misleh, MSN, FNP-C breaks down what the rename actually means. Why the old name pointed providers toward the wrong organ and the wrong mechanism. Why so many women with every sign of the condition were told they did not have it because their ovaries looked clear. And why the framework HRT University has taught from the start, relative estrogen dominance layered on sluggish detoxification, gut-driven estrogen recycling, compromised thyroid, and a metabolic engine forced into glycolysis, is the same physiology the new name finally reflects.

If you have been treating PCOS the way you were taught and something never sat right, this episode is the reframe. The name changed. The mechanism did not.

The HRT University Master Course is jointly accredited through Pinnacle Conference, LLC (ACCME, ACPE, ANCC). Earn 30 CE hours, including 12 hours of pharmacology.

Master Course: https://bit.ly/4twBb0D

Nico's weekly clinical email: https://nicomislehnp.kit.com/8050eeea5f

Provider community: https://www.facebook.com/groups/1179376819949373/

You hired a logo designer, picked your brand colors, maybe even named your clinic something clever. And now you are ready to hand the whole thing to an ad agency and watch the patients roll in. Except that is not how it works. Not even close.

In this episode, Nico Misleh, MSN, FNP-C walks through how to market a medical practice from scratch, and why spending money on agencies before you have done the foundational work is one of the fastest ways to burn cash as a new practice owner. He talks about the daily email practice that shaped his own voice over eighteen months, the Facebook group strategy that builds community without feeling like a sales pitch, and why your social media content is probably talking to your colleagues instead of your patients.

He also breaks down the esthetics example that keeps showing up in provider marketing: the Moxi 3000 announcement that impresses other clinicians and confuses every cold lead who reads it. Then he flips it into a story-driven version that actually speaks to the patient sitting on the other side of the screen.

If you have been wondering why your content is not converting or why your marketing feels like it is missing something, this episode lays out the organic playbook that comes before the ad spend.

HRT University is a physiology-first clinical education program for licensed providers. Jointly accredited through Pinnacle Conference LLC (ACCME, ACPE, ANCC) for 30 CEUs.

Learn more about HRT University: https://bit.ly/4twBb0D

HRTU Newsletter: https://nicomislenp.kit.com/8050eeea5f

Facebook Group: https://www.facebook.com/groups/1179376819949373/

This week I'm switching from clinical to business. I want to talk about the stuff nobody told me when I was building my own clinic. Apollo Health Optimization is three years in now, and it's been the best decision of my life, professionally and personally. Most providers approach building a cash-pay HRT clinic backwards. They start with the brand, the marketing, the website, and treat the clinical work as something they'll catch up on once patients are flowing in. The clinical foundation is not a prerequisite for the business. It IS the business.

In this episode I walk through the mug analogy, the surgeon analogy, why patients can feel the difference between real clinical mastery and the performance of it, and why my friend Ashley got 200 patients in her first year doing almost no traditional marketing. I get into the donut-shop comparison for why word of mouth runs medicine, the brick-and-mortar to virtual transition I made at Apollo, why geography is now irrelevant for a cash-pay HRT clinic, and the predatory equipment sales and marketing agencies you should not be writing checks to in year one. I close with the four-step sequence I'd follow if I were starting today: clinical mastery, then reps with patients, then a practice model that emerges from the clinical work, then the brand on top of all of it.

If you're a provider weighing the move out of insurance, or you've already made it and the practice isn't building the way you thought it would, this one is for you.

00:00 Switching from clinical to business, the stuff nobody told me01:32 Apollo three years in, the best decision of my life02:14 The Field of Dreams approach and why providers get it backwards04:08 The clinical foundation IS the business05:10 The mug analogy06:46 Built on clinical depth, no traditional marketing07:11 The surgeon analogy, why patients can feel confidence08:30 My friend Ashley and 200 patients in year one08:57 What happens when you fake it for too long09:41 My NP school primary care rotation11:54 Studying hormones obsessively, building the framework12:33 Hormones as a symphony, not separate parts14:26 Word of mouth in medicine vs. the donut shop16:40 Patients call it Nico's Place18:59 The brick-and-mortar to virtual transition20:31 Geography is irrelevant, patients fly in from everywhere22:53 Predatory laser and ultrasound reps23:56 Step one of the sequence: clinical foundation, for real25:01 Step two: actually treat patients, competency builds confidence27:10 Step three: let the practice model emerge from the clinical work29:04 Step four: build the brand last, the whiteboard story31:20 Mastery, practice model, marketing, in that order

The HRT University(R) Master Course is jointly accredited through Pinnacle Conference LLC (ACCME, ACPE, ANCC) for 30 CE hours including 12 hours of pharmacology. Course: https://bit.ly/4twBb0D. Newsletter: https://nicomislenp.kit.com/8050eeea5f. Community: https://www.facebook.com/groups/1179376819949373/.

About the host. Nico Misleh, MSN, FNP-C, is a nurse practitioner, the founder of HRT University, and the owner of Apollo Health Optimization.